NCT04641143
Efficacy and Safety Study of Adjunctive Troriluzole in Obsessive Compulsive Disorder
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
The 50 most recent of 80 versions: 49 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
Notable Results posted: Nov 17, 2026 Show 4 more changesShow less
- Eligibility criteria expanded, about 6 words
- Primary endpoint revised
- Secondary endpoints revised (3)
- Site details revised at 2 of 73 sites
- Minor Trial status: Active, Not Recruiting to Completed
- Enrollment target: estimated 700 to confirmed 456
- Primary and study completion dates changed from estimate of Nov 2025 to Oct 27, 2025
- Minor Trial status: Recruiting to Active, Not Recruiting
- Study sites: 96 to 73
- Primary and study completion dates: Jun 2025 to Nov 2025
- Minor Site details revised at 1 of 96 sitesv77
- Minor Site details revised at 2 of 96 sitesv76
Show 44 earlier versionsHide 44 earlier versions
- Minor Site details revised at 1 of 96 sitesv75
- Minor Site details revised at 21 of 96 sitesv74
- Minor Site details revised at 1 of 96 sitesv73
- Minor Site details revised at 17 of 96 sitesv72
- Minor Site details revised at 1 of 96 sitesv71
- Minor Site details revised at 1 of 96 sitesv70
- Minor Study sites: 95 to 96v69
- Minor Study sites: 85 to 95v68
- Minor Primary and study completion dates: Dec 2024 to Jun 2025v67
- Minor Primary and study completion dates: Jun 30, 2024 to Dec 2024v66
- Minor Site details revised at 1 of 85 sitesv65
- Minor Site details revised at 21 of 85 sitesv64
- Notable Primary and study completion dates: Dec 15, 2023 to Jun 30, 2024v63
- Notable Primary and study completion dates: Mar 17, 2023 to Dec 15, 2023v62
- Minor Site details revised at 1 of 85 sitesv61
- Minor Enrollment target: 600 to 700
- Study sites: 92 to 85
- Minor Site contacts updated at 2 of 92 sitesv58
- Minor Site contacts updated at 1 of 92 sitesv57
- Minor Site contacts updated at 1 of 92 sitesv56
- Notable Eligibility criteria shortened, about 12 wordsv55
- Minor Site details revised at 1 of 92 sitesv54
- Minor Site details revised at 1 of 92 sitesv53
- Minor Site details revised at 1 of 92 sitesv52
- Minor Site details revised at 1 of 92 sitesv51
- Minor Site details revised at 1 of 92 sitesv50
- Minor Site details revised at 1 of 92 sitesv49
- Minor Site details revised at 1 of 92 sitesv48
- Minor Study sites: 91 to 92v47
- Minor Site details revised at 2 of 91 sitesv46
- Minor Site details revised at 1 of 91 sitesv45
- Minor Site details revised at 1 of 91 sitesv44
- Minor Site details revised at 1 of 91 sitesv43
- Minor Site details revised at 1 of 91 sitesv42
- Minor Site details revised at 1 of 91 sitesv41
- Minor Site details revised at 1 of 91 sitesv40
- Minor Site details revised at 1 of 91 sitesv39
- Minor Site details revised at 1 of 91 sitesv38
- Minor Site details revised at 1 of 91 sitesv37
- Minor Site details revised at 1 of 91 sitesv36
- Minor Site details revised at 1 of 91 sitesv35
- Minor Site details revised at 1 of 91 sitesv34
- Minor Site details revised at 2 of 91 sitesv33
- Minor Site details revised at 1 of 91 sitesv32
- Minor Site details revised at 2 of 91 sitesv31
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Change From Baseline in the Y-BOCS Total Score in the Baseline Y-BOCS ≥24 Stratification Cohort at Week 8 (Negative Change Indicates Symptom Improvement)
Timeframe: Baseline and Week 8
Secondary (3)
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
Change From Baseline in Sheehan Disability Scale (SDS) Total Score in the Baseline Y-BOCS ≥24 Stratification Cohort at Week 8
Change From Baseline in Clinical Global Impression of Severity (CGI-S) Total Score in the Baseline Y-BOCS ≥24 Stratification Cohort at Week 8
Arms and interventions
TroriluzoleExperimental
Participants received troriluzole 200 milligrams (mg) (100 mg\*2) capsules orally once daily for the first two weeks and up-titrated to 280 mg (140 mg\*2) capsules orally once daily for the next eight weeks, in the double-blind randomization phase.
PlaceboPlacebo comparator
Participants received placebo-matched to troriluzole capsules orally once daily for 10 weeks of the double-blind randomization phase.
Drugs: Troriluzole, Placebo
Sites
73 sites in 1 country